Published in Medical Letter on the CDC and FDA, December 4th, 2005
Bayer and Onyx filed a New Drug Application (NDA) in July 2005 requesting approval in advanced renal cell cancer by the FDA. Subsequently, the FDA granted the Nexavar filing priority review status, which means the FDA intends to make a determination within 6 months of when they received the NDA.
Additionally in September...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.